Home
BIIB
BIIB News

Latest Biogen Inc. (BIIB) News on December 4, 2024

Morningstar Research

2 days ago

Analyst Report: Biogen Inc.

MT Newswires

5 days ago

Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

5 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?

Insider Monkey

6 days ago

Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

PR Newswire

6 days ago

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?

Insider Monkey

7 days ago

Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Investor's Business Daily

8 days ago

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock

Insider Monkey

12 days ago

Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock

Biogen price target lowered to $207 from $251 at Mizuho

TipRanks

12 days ago

Biogen price target lowered to $207 from $251 at Mizuho

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Benzinga

14 days ago

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

MT Newswires

14 days ago

Mizuho Securities Adjusts Price Target on Biogen to $207 From $251

Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now

Insider Monkey

14 days ago

Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now

MT Newswires

15 days ago

Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

GlobeNewswire

15 days ago

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Benzinga

16 days ago

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Investing.com

16 days ago

Needham downgrades Biogen on slow growth of Alzheimer's drug

MT Newswires

16 days ago

Needham Downgrades Biogen to Hold From Buy

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

GlobeNewswire

16 days ago

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?

Insider Monkey

16 days ago

Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?

Morningstar Research

16 days ago

Analyst Report: Biogen Inc.

MT Newswires

19 days ago

Baird Raises Biogen Price Target to $300 From $294, Maintains Outperform Rating

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Zacks

19 days ago

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

European committee takes a second look at Alzheimer's drug and now says it should be approved

Associated Press Finance

20 days ago

European committee takes a second look at Alzheimer's drug and now says it should be approved

5 Healthcare Stocks to Buy in a Beaten-Up Sector

Barrons.com

20 days ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

PR Newswire

20 days ago

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

MT Newswires

20 days ago

Biogen's Alzheimer's Disease Drug Gets Positive Opinion From Europe Regulators

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Zacks

20 days ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Investing.com

20 days ago

Citi initiates coverage on 5 new biotech stocks

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Zacks

20 days ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Zacks

21 days ago

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Zacks

22 days ago

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Zacks

22 days ago

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Morningstar Research

22 days ago

Analyst Report: Biogen Inc.

Morningstar Research

a month ago

Analyst Report: Biogen Inc.

Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated

Zacks

a month ago

Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks

a month ago

BIIB vs. MYGN: Which Stock Is the Better Value Option?

MT Newswires

a month ago

Argus Cuts Biogen's Price Target to $200 From $250

Argus Research

a month ago

Analyst Report: Biogen Inc

Argus Research

a month ago

Market Update: AMT, BIIB, CHH, GPN, UPS, APTV

Are Investors Undervaluing Biogen (BIIB) Right Now?

Zacks

a month ago

Are Investors Undervaluing Biogen (BIIB) Right Now?

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

a month ago

Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA

Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a month ago

Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

a month ago

RBC Adjusts Biogen's Price Target to $260 From $269

Investing.com

a month ago

Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch

MT Newswires

a month ago

Wells Fargo Adjusts Price Target on Biogen to $190 From $225

MT Newswires

a month ago

Wedbush Adjusts Price Target on Biogen to $187 From $195

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Biogen to $315 From $307

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Biogen to $290 From $320

MT Newswires

a month ago

Barclays Adjusts Price Target on Biogen to $180 From $190

MT Newswires

a month ago

Leerink Partners Adjusts Price Target on Biogen to $290 From $310

MT Newswires

a month ago

Morgan Stanley Downgrades Biogen to Equalweight From Overweight, Adjusts Price Target to $204 From $285

MT Newswires

a month ago

Morgan Stanley Downgrades Biogen to Equalweight From Overweight, Cuts Price Target to $204 From $285

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...

GuruFocus.com

a month ago

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

GlobeNewswire

a month ago

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Investor's Business Daily

a month ago

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

Zacks

a month ago

Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View

Morningstar Research

a month ago

Analyst Report: Biogen Inc.

Biogen and Neomorph enter molecular glue degrader deal

Pharmaceutical Technology

a month ago

Biogen and Neomorph enter molecular glue degrader deal

Biogen (BIIB) Q3 2024 Earnings Call Transcript

Motley Fool

a month ago

Biogen (BIIB) Q3 2024 Earnings Call Transcript

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Zacks

a month ago

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

a month ago

Biogen (BIIB) Reports Q3 Earnings: What Key Metrics Have to Say

Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates

Zacks

a month ago

Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates

Biogen, Sage admit a defeat in major depression

BioPharma Dive

a month ago

Biogen, Sage admit a defeat in major depression

Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum

Investor's Business Daily

a month ago

Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum

Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations

Yahoo Finance

a month ago

Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations

MT Newswires

a month ago

Biogen Q3 Adjusted Earnings, Revenue Decline; Raises 2024 Adjusted EPS Guidance

Investing.com

a month ago

Biogen raises annual earnings guidance, tops Q3 estimates; shares up

Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth

Bloomberg

a month ago

Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth

Biogen raises annual profit forecast as new treatments boost earnings

Reuters

a month ago

Biogen raises annual profit forecast as new treatments boost earnings

MT Newswires

a month ago

Biogen, Neomorph Form Multi-Target Research Collaboration on Molecular Glue Degraders

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

GlobeNewswire

a month ago

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Eli Lilly Q3 earnings expected to beat Wall Street expectations

Yahoo Finance

a month ago

Eli Lilly Q3 earnings expected to beat Wall Street expectations

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

GlobeNewswire

a month ago

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen refreshes its C-suite; Novartis writes down MorphoSys assets

BioPharma Dive

a month ago

Biogen refreshes its C-suite; Novartis writes down MorphoSys assets

Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks

a month ago

Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

MT Newswires

a month ago

Biogen Finance Chief Michael McDonnell to Retire; Successor Named

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

GlobeNewswire

a month ago

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

MT Newswires

a month ago

Biogen Says Phase 2 Trial of Felzartamab Shows 'Substantial Reductions' in Proteinuria Levels, Kidney Function Stabilization

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire

a month ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

a month ago

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?

Zacks

a month ago

Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

GlobeNewswire

a month ago

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

Is Eli Lilly Stock A Sell After U.K. Officials — But Not Insurers — Sign Off On Alzheimer's Drug?

Investor's Business Daily

a month ago

Is Eli Lilly Stock A Sell After U.K. Officials — But Not Insurers — Sign Off On Alzheimer's Drug?

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

a month ago

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Zacks

a month ago

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

Zacks

a month ago

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

Morningstar Research

a month ago

Analyst Report: Biogen Inc.

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

GlobeNewswire

a month ago

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now

Insider Monkey

a month ago

Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now

Is Biogen Inc. (BIIB) the Best QQQ Stock to Buy According to Analysts?

Insider Monkey

a month ago

Is Biogen Inc. (BIIB) the Best QQQ Stock to Buy According to Analysts?

Biogen Inc. (BIIB): Worst Performing NASDAQ Stock in 2024

Insider Monkey

a month ago

Biogen Inc. (BIIB): Worst Performing NASDAQ Stock in 2024

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

Benzinga

2 months ago

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

MT Newswires

2 months ago

BMO Capital Adjusts Price Target on Biogen to $230 From $260

State Street Corp's Strategic Acquisition of Biogen Inc Shares

GuruFocus.com

2 months ago

State Street Corp's Strategic Acquisition of Biogen Inc Shares

Biogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects

Insider Monkey

2 months ago

Biogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects

MT Newswires

2 months ago

Morgan Stanley Adjusts Price Target on Biogen to $285 From $291

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Zacks

2 months ago

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen scores breakthrough status for anti-rejection transplant medication

Pharmaceutical Technology

2 months ago

Biogen scores breakthrough status for anti-rejection transplant medication

MT Newswires

2 months ago

Raymond James Downgrades Biogen to Market Perform

Share on Social Networks: